~ Pulse Biosciences’ CellFX System powered by NPS technology
will be featured during four oral presentations of clinical studies
conducted in Sebaceous Hyperplasia, Common Cutaneous Warts, Back
Acne and Common Nevi (Moles) at the premier international meeting
in the field of energy-based technologies attended by top
dermatologists and other skin specialists
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company introducing the CellFX System powered by
Nano-Pulse Stimulation™ (NPS™) technology, today announced the
podium presentation of four clinical studies of NPS technology at
the American Society for Laser Medicine and Surgery (ASLMS) Virtual
Annual Meeting taking place on May 15-16, 2021. Recent results will
be presented on the use of CellFX’s non-thermal, cellular-specific
NPS technology in clinical feasibility and optimization studies
designed to address a variety of challenging benign skin
lesions.
Nano-Pulse Stimulation (NPS) technology delivers nano-second
pulses of electrical energy to non-thermally clear cells while
sparing adjacent non-cellular tissue, which is largely comprised of
collagen. The distinct advantages of the NPS mechanism have the
potential to improve clinical and aesthetic outcomes by clearing
benign lesions where important treatment gaps exist.
Abstracts demonstrating the ability of NPS technology to clear
Back Acne, Common Nevi (Moles), Sebaceous Hyperplasia (SH) and
Cutaneous Warts will be presented by dermatologic surgeons Dr.
Bruce Katz of New York, NY; Dr. Joel Cohen of Denver, CO; Dr.
Suzanne Kilmer of Sacramento, CA; and Dr. Ted Lain of Austin, TX,
respectively.
Dr. Bruce Katz, Director of JUVA Skin & Laser Center and
Clinical Professor of Dermatology at The Icahn School of Medicine
at Mount Sinai, New York City, commented, “I am excited that the
results from our feasibility study to clear back acne further
support the promising efficacy of NPS’ cellular mechanism on the
sebaceous glands that contribute to acne eruptions. We were also
intrigued to observe a potential effect of acne lesion reduction
beyond the treated skin areas, which is encouraging.”
“We are proud to have four abstracts accepted for oral
presentation at this prestigious global meeting and applaud our
investigators whose rigorous scientific studies provide clinical
evidence of the differentiated benefits and broad applicability of
NPS technology,” said Ed Ebbers, Executive Vice President and
General Manager, Dermatology for Pulse Biosciences. “Their vital
learnings are crucial not only to advancing our CellFX procedure in
real-world clinical practice with the dermatology thought-leaders
currently participating in our controlled commercial launch, but
also to expanding interest in NPS technology among the next wave of
early adopters.”
NPS Technology Presentations Schedule
“Multi-Center Study of Nano-Pulse Stimulation (NPS) Technology
for the Treatment of Moderate-to-Severe Acne Vulgaris of the Back:
A Feasibility Study” by Bruce Katz, MD [11:18-11-23 a.m. CT,
Sunday, May 16]
- Results demonstrate NPS procedure’s ability to treat
moderate-to-severe back acne
- Potential regional effect, extending to acne lesions outside
NPS-treated skin areas
“A Feasibility Study of Non-Thermal Nano-Pulse Stimulation (NPS)
Technology for Treating Common Nevi” by Joel Cohen, MD [11:23-11:28
a.m. CT, Sunday, May 16]
- Data suggest NPS procedure may be effective for treating common
nevus lesions.
- Junctional nevi may have better single-treatment clearance, and
compound/ intradermal nevi may require an additional NPS
session.
“Lower Energy Settings with Nano-Pulse Stimulation (NPS)
Procedure to Treat Sebaceous Hyperplasia Yield High Efficacy and
Superior Skin Recovery” by Suzanne Kilmer, MD [11:28-11:33 a.m. CT,
Sunday May 16]
- Validates NPS procedure for treating sebaceous hyperplasia
- High efficacy was achieved with greatly reduced energy
settings
- Single NPS procedure with lowest setting cleared majority of
lesions with low rates of transient skin effects.
“Non-Thermal Nano-Pulse Stimulation (NPS) Procedure for Treating
Cutaneous, Non-Genital Warts Shows High Clearance Efficacy with a
Single Session” by Ted Lain, MD [11:33-11:38 a.m. CT, Sunday, May
16]
- Applicability of NPS procedure to treat non-genital warts
- Overall complete clearance rate for common warts was 75%
- A majority (81%) of common warts completely cleared using a
single session, including recalcitrant warts
A live discussion on NPS technology with the presenting authors
will also take place from 11:38-11:43 am CT. Content will be
available to registered participants live on the ASLMS website
during the conference and on-demand for 60 days after the
conference.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The CellFX® System is the first
commercial product to harness the distinctive advantages of the
Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology,
such as the ability to non-thermally clear cells while sparing
non-cellular tissue, to treat a variety of applications for which
an optimal solution remains unfulfilled. Nano-Pulse Stimulation
technology delivers nano-second pulses of electrical energy. The
initial commercial use of the CellFX System is to address a range
of dermatologic conditions that share high demand among patients
and practitioners for improved dermatologic outcomes. Designed as a
multi-application platform, the CellFX System offers customer value
with a utilization-based revenue model.
To stay informed about the CellFX System, please visit
CellFX.com and sign-up for updates. ASLMS registrants may also
visit the Pulse Biosciences virtual exhibit booth in the ASLMS
Innovations Center on May 15 - 16, 2021.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the
stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to Pulse Biosciences’ expectations regarding
the benefits of the Company’s Controlled Launch program and
commercialization of the CellFX System, including the timing for
onboarding KOLs, regulatory clearance and the timing of FDA, Health
Canada and other regulatory filings or approvals, including the
ability of the Company to successfully complete a 510(k) submission
for the CellFX System for other dermatologic indications, NPS
technology including the effectiveness of such technology, the
CellFX System including the benefits of the CellFX System, current
and planned future clinical studies, the timing for completion of
such studies, and the ability of the Company to execute such
studies and the results of any such studies, other matters related
to its pipeline of product candidates, the Company’s market
opportunity and commercial launch plans, including the market for
aesthetic dermatologic procedures and the willingness of consumers
to pay premium out-of-pocket fees for treatments, and expectations
regarding adoption of the CellFX System, additional applications of
the CellFX System outside of aesthetic dermatology, future
financial performance, the impact of COVID-19 and other future
events. These statements are not historical facts but rather are
based on Pulse Biosciences’ current expectations, estimates, and
projections regarding Pulse Biosciences’ business, operations and
other similar or related factors. Words such as “may,” “will,”
“could,” “would,” “should,” “anticipate,” “predict,” “potential,”
“continue,” “expects,” “intends,” “plans,” “projects,” “believes,”
“estimates,” and other similar or related expressions are used to
identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Pulse Biosciences’ control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Pulse
Biosciences’ filings with the Securities and Exchange Commission.
Pulse Biosciences undertakes no obligation to revise or update
information in this release to reflect events or circumstances in
the future, even if new information becomes available.
EDITOR’S NOTE: Pulse
Biosciences will host a virtual exhibit booth at the ASLMS meeting
where attendees may speak with CellFX representatives via chat
and/or by scheduling one-on-one appointments in advance and during
the conference via the online SmartMatch program.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513005632/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Media: Tosk Communications Nadine D. Tosk 504.453.8344
nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
